Sujal Shah - 24 Jan 2024 Form 4 Insider Report for CymaBay Therapeutics, Inc. (CBAY)

Role
Chief Executive Officer, Director
Signature
/s/ Paul Quinlan, as attorney-in-fact for Sujal Shah
Issuer symbol
CBAY
Transactions as of
24 Jan 2024
Net transactions value
$0
Form type
4
Filing time
26 Jan 2024, 18:27:47 UTC
Previous filing
11 Dec 2023
Next filing
15 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Award $0 +96,250 +56% $0.000000 267,551 24 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Award $0 +357,500 $0.000000 357,500 24 Jan 2024 Common Stock 357,500 $22.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The grant shall vest as to 1/4 of the shares on each of January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028.
F2 The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2024.